For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
The closing price of Standard BioTools Inc (NASDAQ: LAB) was $1.27 for the day, up 3.25% from the previous closing price of $1.23. In other words, the price has increased by $3.25 from its previous closing price. On the day, 1.76 million shares were traded. LAB stock price reached its highest trading level at $1.32 during the session, while it also had its lowest trading level at $1.24.
Ratios:
Our analysis of LAB’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.92 and its Current Ratio is at 5.16. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
On April 16, 2024, TD Cowen started tracking the stock assigning a Buy rating and target price of $3.50.TD Cowen initiated its Buy rating on April 16, 2024, with a $3.50 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 15 ’25 when Casdin Partners Master Fund, L bought 150,000 shares for $1.22 per share. The transaction valued at 183,210 led to the insider holds 59,750,000 shares of the business.
Casdin Partners Master Fund, L bought 133,220 shares of LAB for $161,543 on Aug 14 ’25. The Director now owns 59,600,000 shares after completing the transaction at $1.21 per share. On Aug 13 ’25, another insider, Casdin Partners Master Fund, L, who serves as the Director of the company, bought 75,000 shares for $1.31 each. As a result, the insider paid 98,280 and bolstered with 59,466,780 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LAB now has a Market Capitalization of 485133664 and an Enterprise Value of 180545040. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.15 while its Price-to-Book (P/B) ratio in mrq is 1.14. Its current Enterprise Value per Revenue stands at 1.048 whereas that against EBITDA is -1.48.
Stock Price History:
The Beta on a monthly basis for LAB is 1.29, which has changed by -0.3172043 over the last 52 weeks, in comparison to a change of 0.15222645 over the same period for the S&P500. Over the past 52 weeks, LAB has reached a high of $2.32, while it has fallen to a 52-week low of $0.92. The 50-Day Moving Average of the stock is 1.27%, while the 200-Day Moving Average is calculated to be -9.42%.
Shares Statistics:
LAB traded an average of 1.83M shares per day over the past three months and 1211080 shares per day over the past ten days. A total of 381.69M shares are outstanding, with a floating share count of 363.35M. Insiders hold about 4.34% of the company’s shares, while institutions hold 73.68% stake in the company. Shares short for LAB as of 1753920000 were 12009245 with a Short Ratio of 6.55, compared to 1751241600 on 12873448. Therefore, it implies a Short% of Shares Outstanding of 12009245 and a Short% of Float of 5.390000000000001.
Earnings Estimates
The current assessment of Standard BioTools Inc (LAB) involves the perspectives of 1.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.04, with high estimates of -$0.04 and low estimates of -$0.04.
Analysts are recommending an EPS of between -$0.14 and -$0.14 for the fiscal current year, implying an average EPS of -$0.14. EPS for the following year is -$0.11, with 1.0 analysts recommending between -$0.11 and -$0.11.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 3 analysts. It ranges from a high estimate of $43.4M to a low estimate of $17.7M. As of the current estimate, Standard BioTools Inc’s year-ago sales were $44.97MFor the next quarter, 3 analysts are estimating revenue of $28.2M. There is a high estimate of $46.2M for the next quarter, whereas the lowest estimate is $18.4M.
A total of 3 analysts have provided revenue estimates for LAB’s current fiscal year. The highest revenue estimate was $171M, while the lowest revenue estimate was $78M, resulting in an average revenue estimate of $109.9M. In the same quarter a year ago, actual revenue was $174.43MBased on 3 analysts’ estimates, the company’s revenue will be $115.33M in the next fiscal year. The high estimate is $187.8M and the low estimate is $78.7M.
